Stem cells, immortalized cells and primary cells in ADMET assays

Michael W Sinz; Sean Kim

doi:10.1016/j.ddtec.2006.03.006

Stem cells, immortalized cells and primary cells in ADMET assays

Drug Discov Today Technol. 2006 Spring;3(1):79-85. doi: 10.1016/j.ddtec.2006.03.006.

Authors

Michael W Sinz¹, Sean Kim²

Affiliations

¹ Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492, USA. Electronic address:[email protected].
² Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492, USA.

PMID: 24980105
DOI: 10.1016/j.ddtec.2006.03.006

Abstract

Cell-based assays are beginning to replace traditional absorption, distribution, metabolism, elimination and toxicology (ADMET) models employing subcellular fractions in high throughput drug discovery screening and drug development where drugs are characterized and predictions are formulated to forecast in vivo biological outcomes. Significant and continuing advances in stem cell research, new immortalized cell lines and our enhanced ability to predict outcomes from primary cells have increased the ability to employ cell-based assays to study ADMET properties of new drugs.: